These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

618 related articles for article (PubMed ID: 12135670)

  • 1. In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia.
    La Rosée P; Johnson K; O'Dwyer ME; Druker BJ
    Exp Hematol; 2002 Jul; 30(7):729-37. PubMed ID: 12135670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro.
    Mow BM; Chandra J; Svingen PA; Hallgren CG; Weisberg E; Kottke TJ; Narayanan VL; Litzow MR; Griffin JD; Sausville EA; Tefferi A; Kaufmann SH
    Blood; 2002 Jan; 99(2):664-71. PubMed ID: 11781252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines.
    La Rosée P; Johnson K; Corbin AS; Stoffregen EP; Moseson EM; Willis S; Mauro MM; Melo JV; Deininger MW; Druker BJ
    Blood; 2004 Jan; 103(1):208-15. PubMed ID: 12933582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VEGF depletion enhances bcr-abl-specific sensitivity of arsenic trioxide in chronic myelogenous leukemia.
    Luo X; Feng M; Zhu X; Li Y; Fei J; Zhang Y
    Hematology; 2013 Nov; 18(6):334-40. PubMed ID: 24129092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arsenic trioxide and bortezomib interact synergistically to induce apoptosis in chronic myelogenous leukemia cells resistant to imatinib mesylate through Bcr/Abl‑dependent mechanisms.
    Xu W; Wei W; Yu Q; Wu C; Ye C; Wu Y; Yan H
    Mol Med Rep; 2014 Sep; 10(3):1519-24. PubMed ID: 24939418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Arsenic trioxide inhibits cell growth in imatinib-resistant bcr-abl mutant cell lines in vitro].
    Lu RZ; Qiu L; Wang XD; Li XF; Chen LJ; Wang XL; Zhang BL; Ma J
    Zhonghua Xue Ye Xue Za Zhi; 2009 Jan; 30(1):13-7. PubMed ID: 19563028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [STI571 enhances the effect of arsenic trioxide and Velcade on bcr/abl+-CD34+ cell proliferation and apoptosis].
    Li CY; Meng FY; Sun QX; Fu YB; Li L; Yi ZS; Song LL
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Nov; 27(11):1665-9. PubMed ID: 18024285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The new iodoacetamidobenzofuran derivative TR120 decreases STAT5 expression and induces antitumor effects in imatinib-sensitive and imatinib-resistant BCR-ABL-expressing leukemia cells.
    Grimaudo S; Meli M; Di Cristina A; Ferro A; Pipitone MR; Romagnoli R; Simoni D; Dieli F; Tolomeo M
    Anticancer Drugs; 2013 Apr; 24(4):384-93. PubMed ID: 23370613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
    Hekmatshoar Y; Ozkan T; Altinok Gunes B; Bozkurt S; Karadag A; Karabay AZ; Sunguroglu A
    Cell Mol Biol (Noisy-le-grand); 2018 May; 64(6):23-30. PubMed ID: 29808796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro.
    Wu LX; Wu Y; Chen RJ; Liu Y; Huang LS; Lou LG; Zheng ZH; Chen YZ; Xu JH
    Acta Pharmacol Sin; 2014 Mar; 35(3):401-9. PubMed ID: 24487968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced Bcr-Abl-specific antileukemic activity of arsenic trioxide (Trisenox) through glutathione-depletion in imatinib-resistant cells.
    Konig H; Härtel N; Schultheis B; Schatz M; Lorentz C; Melo JV; Hehlmann R; Hochhaus A; La Rosée P
    Haematologica; 2007 Jun; 92(6):838-41. PubMed ID: 17550858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No correlation between the proliferative status of Bcr-Abl positive cell lines and the proapoptotic activity of imatinib mesylate (Gleevec/Glivec).
    La Rosée P; Shen L; Stoffregen EP; Deininger M; Druker BJ
    Hematol J; 2003; 4(6):413-9. PubMed ID: 14671613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Synergistic inhibitory effect of STI571 in combination with arsenic trioxide on a multidrug-resistant leukemia cell line expressing bcr-abl].
    Chen L; Wang JM; Xu XP; Gao L; Fei XH; Lou JW; Huang ZX
    Zhonghua Zhong Liu Za Zhi; 2004 Sep; 26(9):535-8. PubMed ID: 15555283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
    O'Hare T; Pollock R; Stoffregen EP; Keats JA; Abdullah OM; Moseson EM; Rivera VM; Tang H; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Shakespeare WC; Dalgarno D; Clackson T; Sawyer TK; Deininger MW; Druker BJ
    Blood; 2004 Oct; 104(8):2532-9. PubMed ID: 15256422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells.
    Al-Jamal HA; Jusoh SA; Yong AC; Asan JM; Hassan R; Johan MF
    Asian Pac J Cancer Prev; 2014; 15(11):4555-61. PubMed ID: 24969884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells.
    Topaly J; Zeller WJ; Fruehauf S
    Leukemia; 2001 Mar; 15(3):342-7. PubMed ID: 11237055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endoplasmic reticulum stress-mediated apoptosis in imatinib-resistant leukemic K562-r cells triggered by AMN107 combined with arsenic trioxide.
    Xia Y; Fang H; Zhang J; Du Y
    Exp Biol Med (Maywood); 2013 Aug; 238(8):932-42. PubMed ID: 23883479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L).
    Perkins C; Kim CN; Fang G; Bhalla KN
    Blood; 2000 Feb; 95(3):1014-22. PubMed ID: 10648417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells.
    Scappini B; Onida F; Kantarjian HM; Dong L; Verstovsek S; Keating MJ; Beran M
    Cancer; 2002 May; 94(10):2653-62. PubMed ID: 12173333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL--expressing cells, demonstrating synergy between AG490 and STI571.
    Sun X; Layton JE; Elefanty A; Lieschke GJ
    Blood; 2001 Apr; 97(7):2008-15. PubMed ID: 11264165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.